Français

Halving the price of artificial organs and bionic prostheses

 

 

What is Hélice ?

 

The Hélice company aims at drastically reducing the price of bionic prostheses and artificial organs such as retinal implants, heart prosthesis, exoskeletons etc,.

These technologies are very expensive (≈ 100 000€).

Unfortunately, this sector is developing very slowly.

Indeed, among other particular factors, these are very customized, which is why there is no large-scale production possible.

Hélice has therefore designed innovative financial engineering based on blockchain technology to halve the price of prostheses without any changes being made to the prosthesis ! 

How does it work ?*

*A French version is also available

Why acquire $Helice ?

A Real Utility And Impact

Thanks to the token many patients will access to highly sophisticated prostheses capable of greatly improving their lives or even saving them. Thanks to this beneficial impact on society, the Hélice token can acquire a great visibility. Moreover, if you own tokens then this gives you priority access to discounted prostheses

Hyper Deflationary Token

$Helice is unique. Our token has a maximum supply of 1 unit. 

You will never see your savings diluted by new tokens created by an unscrupulous team!

In addition, the recurring buyback and burn of the Hélice model will further decrease the supply as time goes on.

 

N

Earn*

Owner of $Helice can earn 1.1% transaction fees. Indeed, transaction fees are the main source of revenue for almost all exchanges, but since we make money selling prostheses, a part of these fees will be given to users !

Own Tokens Of A Strong Company

Hélice is a company based in France and subject to French and European regulations. Our competitive advantage is that we can sell prostheses at lower prices than our competitors without making any modification to the prosthesis. This market will exceed $53 billion by 2027 and demand will increase as the technology improves.  One day, we hope to be able to distribute a dividend (when regulations allow).

BuyBack & Burn

Liquidity is continuously fed back into the model. Indeed, after a patient purchases the prosthesis (Figure 2), Hélice realizes a buyback. This liquidity comes from a real creation of value and puts buying pressure on the token.  Then, Hélice performs  a  burn of its own token, thus progressively reducing the total supply overtime and making the Hélice token even more scarce… 

Be Part Of The Disruption

Hélice is part of a “disruptive” approach to the sector, first by radically reducing prices for as many patients as possible to benefit from them, and then, by using the capital to invest substantially in order to improve these technologies. Without Hélice intervention, such a process would normally be extremely slow given the particular factors of our sector as mentioned above. But thanks to Hélice, this process will be strongly speeded up and 2030 will be the new 2050 !

*This does not represent a financial entitlement. Hélice can reduce or eliminate the amount allocated at its own discretion.

A Real Utility And Impact

Thanks to the token many patients will access to highly sophisticated prostheses capable of greatly improving their lives or even saving them. Thanks to this beneficial impact on society, the Hélice token can acquire a great visibility. Moreover, if you own tokens then this gives you priority access to discounted prostheses

Hyper Deflationary Token

$Hélice is unique. Our token has a maximum supply of 1 unit. 

You will never see your savings diluted by new tokens created by an unscrupulous team!

In addition, the recurring buyback and burn of the Hélice model will further decrease the supply as time goes on.

 

N

Earn*

Owner of $Hélice can earn 1.1% transaction fees. Indeed, transaction fees are the main source of revenue for almost all exchanges, but since we make money selling prostheses, a part of these fees will be given to users !

Own Tokens Of A Strong Company

Hélice is a company based in France and subject to French and European regulations. Our competitive advantage is that we can sell prostheses at lower prices than our competitors without making any modification to the prosthesis. This market will exceed $53 billion by 2027 and demand will increase as the technology improves.  One day, we hope to be able to distribute a dividend (when regulations allow).

BuyBack & Burn

Liquidity is continuously fed back into the model. Indeed, after a patient purchases the prosthesis (Figure 2), Hélice realizes a buyback. This liquidity comes from a real creation of value and puts buying pressure on the token.  Then, Hélice performs  a  burn of its own token, thus progressively reducing the total supply overtime and making the Hélice token even more scarce… 

Be Part Of The Disruption

Hélice is part of a “disruptive” approach to the sector, first by radically reducing prices for as many patients as possible to benefit from them, and then, by using the capital to invest substantially in order to improve these technologies. Without Hélice intervention, such a process would normally be extremely slow given the particular factors of our sector as mentioned above. But thanks to Hélice, this process will be strongly speeded up and 2030 will be the new 2050 !

*This does not represent a financial entitlement. Hélice can reduce or eliminate the amount allocated at its own discretion.

A first patient in 2021

Dylan was the first person to take advantage of the Hélice program, in an amount of 107,000€. This program allowed him to acquire the most sophisticated knee prosthesis in the world (Genium x3) through the sale of tokens to early investors (who will have access to it after the public sale of the token).

Roadmap

2021

First use case with Dylan

Presale & Partnerships

2023

First halving of our
partners’ price and first buyback-burn.

2023

More than 100 patients fitted with the most advanced prostheses

2025/2026

Creation of the Hélice Model

Presentation to the community

2023

Token available on a Cex or/and on the Hélice platform.

2023

First milestone (not disclosed at this stage)

2023/2024

Creation of an R&D laboratory

Roadmap

2021

Creation of the Hélice Model

First use case with Dylan

Presentation to the community

2023

Presale & Partnerships

2023

Token available on a Cex or/and on the Hélice platform.

2023

First halving of our
partners’ price and first buyback-burn.

2023

Continuation of the
process until the Hélice token reaches a price/market cap of $100M.

2023/2024

More than 100 patients fitted with the most advanced prostheses

2023/2024

First milestone (not disclosed at this stage)

2025/2026

Creation of an R&D laboratory

Advisors & Team (non-exhaustive)

Bernard Verrier | Ph.D In Biology

 Director of the « Tissue Biology and Therapeutic Engineering » department at the IBCP (CNRS & University of Lyon).

Born in France in 1957 and trained as a chemist, before getting a phD in molecular virology in 1985 and post-doctorated for three years at the EMBL, Germany, in retroviral oncology. Then, he moved to Lyon (France) to study human retrovirology, designing HIV vaccine candidates, either therapeutic, using tat,rev or nef regulatory proteins or prophylactic, with gp140 constructs, through a permanent position at CNRS. Director of research from CNRS since 2004, he was head of a joint unit between CNRS and bioMerieux, dedicated to HIV and HCV therapeutic vaccines.

Anton Sindali | Surgeon

 Doctor of Medicine thesis (hepatic surgery).
– Diplomas of 3rd cycles of university studies in Marseille (Aix- Marseille II): Qualified in General Surgery, University Diploma in Anaesthesia – Intensive Care, University Diploma in Pathological Anatomy, University Diploma in Abdominal Ultrasound, University Diploma in Digestive Endoscopy.
– Diplomas of 3rd cycles of university studies in Paris (Paris XI): University Diploma in Laparoscopic Abdominal Surgery (Paris School of Surgery, Kremlin-Bicètre), University Diploma in Clinical Oncology Villejuif (IGR).

 

Denis Chriqui | Ph.D In Economics

Economist and former professional trader. After a Ph.D in economics from the University of Montpellier and training at the Wharton School, Denis was for more than 16 years a business buyer, professor of economics, specialist and researcher in behavioral finance, trainer in technical analysis and director of an import-export company. He worked as a professional trader in New York at Herzog Heine Geduld (Merrill Lynch) and E Trade for more than 6 years as an arbitrageur-strategist on derivatives, then in portfolio management and front office manager. Since 2004, Denis has been devoting himself to his vocation for teaching and proprietary trading.

Thierry Monmasson | Ph.D In Pharmaceutical Sciences

 1993: Pharmacist Diploma: six-year university degree in industrial pharmacy with honors at the University of Pharmacy of Marseille. 1998: Master degree in Sciences, speciality Biochemistry and genetics at the University of medecine of Marseille. 1999: Diplôme d’études approfondies: one-year degree before postgraduate studies in cellular and molecular biology at the University of medecine of Marseille.
RESEARCH : Study of chaperone proteins and thyroid hormonegenesis, contribution to the study of the action of the disulfide isomerase protein in the thyroglobulin metabolism. 

Samuel G. Ongala-Eedoumou I MSc In Physics

Master’s Degree – Magnetic Fusion Confinement Université Pierre et Marie Curie (Paris VI) 2012 – 2015

Diploma in Basic Physics International Center for Theoretical Physics Trieste, Italy 2011 – 2012

Maitrise de Physique Université Marien Ngouabi Congo 2009 – 2010

Licence de Physique Université Marien Ngouabi Congo 2008 – 2009

Olivier Rousselle | Ph.D In Quantum Physics

Passionate by science and by the universe, Olivier has obtained a PhD in quantum physics at Sorbonne Université in 2022. He has dealt with different research topics until now: particle physics and software development at CERN; foundations of quantum physics at ENS; modeling and statistics at CNRS; biology and environmental studies at AgroParisTech. Moreover, he is passionate about the crypto / blockchain ecosystem, and he is currently involved in the development of efficient crypto algorithmic bots.

Curriculum : PhD in Physics at Sorbonne Université (2019-2022).

Master in Theoretical Physics at Aix-Marseille Université (2018-2019).

Engineer School AgroParisTech (2013-2017).

Adrien Marchand | MSc In International Finance

ESM IAE Metz Master 2, International Finance · (2017 – 2018)

Saint Petersburg State University of Economics. Master 1 International Management · (2016 – 2017)

Université d’Angers – Bachelor of Science in Economics and International management · (2015 – 2016).

Florian Ravaz | Ph.D In Law

2007-2010 : Law degree (University of Toulon)

2010-2011 : Master of Law, Mention public law and private law (University of Toulon)

2011-2012 : Master of Notarial Law (University of Toulon).

2012-2016 : PhD in public law on « Taxation of non -resident foreigners in France », very honorable mention (University of Toulon).

Jérôme Sohier | Ph.D in Biomedical engineering

Researcher at the « Tissue Biology and Therapeutic Engineering » department at the IBCP (CNRS & University of Lyon).

Born in France in 1976 and trained as a polymer chemist, Dr. Sohier was a junior researcher in the first European tissue engineering company (IsoTis) prior to obtaining a Ph.D. in biomedical engineering from the university of Twente (Netherlands) in 2006. He then continued his studies and developments of regenerative medicine strategies in post-doctoral appointments in Nantes (Lab. of osteoarticular and dental engineering INSERM) and London (Imperial College, National Heart and Lung Institute). He has a strong interest in translating his research to patients needs and had the opportunity of participating in the creation of a startup company dedicated to bone repair, based on an innovative technology that he invented.  Since 2012, he is a permanent researcher in Lyon, where he continues to develop translatable approaches to repair and regenerate various tissues, for which there are no therapeutic alternatives.

Jaime Lourenço | Ph.D In Economics

Héloïse Ravaz | Founder & CEO Of Hélice

Lucas Ewig I Master in Management & MSc in Corporate Financial Management

Master in Management & MSc Corporate Financial Management
SKEMA Business School – 2022
-Blockchain & Cryptocurrencies
-Corporate Finance & Financial Markets

Bachelor’s degree in Economics and Management – Faculty of Economics and Management of Strasbourg – 2019
(top 3% of promotion)

Bernard Verrier | Ph.D In Biology

Anton Sindali | Surgeon

Denis Chriqui | Ph.D In Economics

Thierry Monmasson | Ph.D In Pharmaceutical Sciences

Olivier Rousselle | Ph.D In Quantum Physics

Florian Ravaz | Ph.D In Law

Jaime Lourenço | Ph.D In Economics

Héloïse Ravaz | Founder & CEO Of Hélice

Samuel G. Ongala-Eedoumou I MSc In Physics

Adrien Marchand | MSc In International Finance

Lucas Ewig I Master in management / MSc in corporate financial management

PARTNERS 

HCS Pharma

Adjuvatis

Exoneo

Keep Walking

Gyrolift

S.O.P

Keep Walking

Gyrolift

S.O.P

In The Press

Are you ready to disrupt this technology ? Join the airdrop (limited) :

HÉLICE PROSTHESIS

9A Boulevard de Strasbourg 83000 Toulon, France